Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine

Article Biochemistry & Molecular Biology

DIAGNOSTIC PERFORMANCE OF LACTATE DEHYDROGENASE (LDH) ISOENZYMES LEVELS FOR THE SEVERITY OF COVID-19

Ilkay Ergenc et al.

Summary: This study investigated LDH isoenzyme levels in COVID-19 patients to identify the tissue responsible for serum LDH elevation. LDH3 was found to be an independent risk factor for deterioration in COVID-19 patients.

JOURNAL OF MEDICAL BIOCHEMISTRY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

An Interplay between Oxidative Stress (Lactate Dehydrogenase) and Inflammation (Anisocytosis) Mediates COVID-19 Severity Defined by Routine Clinical Markers

Marta Alonso-Bernaldez et al.

Summary: Viral infections cause immune response and inflammation in the body, and also affect oxidative stress markers, potentially affecting the progression of the disease. This research aimed to investigate the role of LDH in oxidative stress and its interaction with inflammation in relation to the severity of COVID-19. The study included 1808 COVID-19 patients from the HM Hospitals database, and regression and mediation analyses were performed. Results showed that patients with lower SaO(2) had lymphopenia, higher neutrophils-to-lymphocytes ratio, and increased anisocytosis. The regression model suggested an interaction between LDH and anisocytosis, with high LDH levels and anisocytosis coefficient >10% impacting SaO(2) in COVID-19 patients. Further analysis showed that LDH mediated 41% of the effect of anisocytosis on SaO(2) in this cohort. This study highlights the importance of LDH and its interaction with anisocytosis in the severity of COVID-19, and emphasizes the need to consider them in the management and treatment of oxidative phenomena associated with the disease.

ANTIOXIDANTS (2023)

添加到收藏夹

Article Virology

Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study

Guangtong Deng et al.

Summary: Chinese guidelines prioritize the use of Azvudine and nirmatrelvir-ritonavir in COVID-19 patients. However, real-world data on their effectiveness is lacking. This study compared the effectiveness of Azvudine versus nirmatrelvir-ritonavir treatments and found that Azvudine showed effectiveness in hospitalized COVID-19 patients in terms of disease progression outcome.

JOURNAL OF MEDICAL VIROLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

China's COVID-19 reopening measures—warriors and weapons

Shujie Huang et al.

LANCET (2023)

添加到收藏夹

Article Medicine, General & Internal

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study

Yuming Sun et al.

Summary: This retrospective cohort study evaluated the clinical efficacy of Azvudine in hospitalised patients with COVID-19 and pre-existing conditions. The results showed that Azvudine treatment was associated with a lower risk of disease progression in these patients. However, there was no significant difference in all-cause death between Azvudine recipients and controls. Hence, Azvudine therapy should be considered for hospitalised COVID-19 patients with pre-existing conditions.

ECLINICALMEDICINE (2023)

添加到收藏夹

Article Public, Environmental & Occupational Health

Inflammatory markers and COVID-19 disease progression

Santosh Kumar Sidhwani et al.

Summary: This study aimed to investigate the correlation between inflammatory markers and the severity of COVID-19. The results showed a significant association between all markers, except procalcitonin, and disease severity. These findings could enhance our understanding of COVID-19 pathogenesis and aid in predicting and managing severe cases.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2023)

添加到收藏夹

Article Hematology

'Immune-inflammatory markers & clinical characteristics for outcomes in hospitalized SARS-CoV-2 infected patients of Pakistan: a retrospective analysis'

Atiqa Khalid et al.

Summary: By evaluating the association between immune-inflammatory markers and the severity and prognosis of COVID-19, physicians can provide timely treatment and ICU admission, thereby reducing the overall mortality of COVID-19 patients.

HEMATOLOGY (2023)

添加到收藏夹

Article Geosciences, Multidisciplinary

Anxiety in patients treated in a temporary hospital in Belgrade, Serbia, during the first epidemic wave of COVID-19

Aleksandar Makevic et al.

Summary: This study found that COVID-19 patients admitted to temporary hospitals often experience anxiety, but their anxiety levels significantly reduce two weeks after discharge. Factors such as sex, age, severity of symptoms, and family history of psychiatric disorder are significant predictors of anxiety levels at admission.

INTERNATIONAL JOURNAL OF DISASTER RISK REDUCTION (2022)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

The first Chinese oral anti-COVID-19 drug Azvudine launched

Bin Yu et al.

INNOVATION (2022)

添加到收藏夹

Letter Medicine, General & Internal

Lactate dehydrogenase, COVID-19 and mortality

Konstantinos Bartziokas et al.

MEDICINA CLINICA (2021)

添加到收藏夹

Letter Emergency Medicine

Lactate dehydrogenase level as a COVID-19 severity marker

Lukasz Szarpak et al.

AMERICAN JOURNAL OF EMERGENCY MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients

Jin-Lan Zhang et al.

Summary: FNC, a nucleoside analog, has shown activity against HIV-1 and SARS-CoV-2. Research suggests FNC's anti-viral effect is concentrated in the thymus, promoting immunity. Clinical trials have demonstrated oral FNC's ability to effectively cure COVID-19 patients.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary